Exchange: NASDAQ
Industry: Biotechnology
Last Trade: 4:00 PM ET 2/9/2012
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | -0.05 | -0.21 | 76.19 |
| EPS, GAAP | -0.05 | -0.21 | 76.19 |
| Consensus Estimate | -0.18 | -0.18 | 0.00 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | -0.81 | -0.72 | -12.50 |
| EPS, GAAP | -0.88 | -0.78 | -12.82 |
| Consensus Estimate | -0.71 | NA | NA |
| ASTM | Industry Average | |
| P/E (TTM) | -2.22 | 86.30 |
| P/E (Forward) | NA | -4.30 |
| PEG Ratio | NA | -0.21 |
| Price/Sales | 277.98 | 4.64 |
| Beta | 0.08 | 1.31 |
| 1/20/2012 | Let's look at this year's prospects for this company. (The Motley Fool) |
| 12/8/2011 | Finding companies that have all the right stuff can produce winners. (The Motley Fool) |
| 11/17/2011 | Geron gives up. So does Wall Street. (The Motley Fool) |
| 11/17/2011 | A list of promising companies chosen by investors who've already picked stocks that beat the market with huge gains. (The Motley Fool) |
| 11/14/2011 | Aastrom's phase 2 and phase 3 trials don't match up. (The Motley Fool) |
![[sm0212smart]](http://s.wsj.net/public/resources/images/PF-AB863_sm0212_C_20120118122431.jpg)
![[smfineprint]](http://s.wsj.net/public/resources/images/PF-AB821_smfine_C_20120111122044.jpg)
![[sm0212funds]](http://s.wsj.net/public/resources/images/PF-AB839_sm0212_C_20120113140400.jpg)
![[sm0212ten]](http://s.wsj.net/public/resources/images/PF-AB840_sm0212_C_20120117120334.jpg)
